Progress in the experimental therapy of severe arenaviral infections

Future Microbiology

Volumn 6, Issue 12, 2011, Pages 1429-1441

  Gowen, Brian B ^a   Bray, Mike ^b  

^a UTAH STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antiviral therapy; Arenavirus; Argentine hemorrhagic fever; Guanarito virus; Jun n virus; Lassa fever; Machupo virus; Sabia virus; Viral hemorrhagic fever

Indexed keywords

ADENINE DERIVATIVE; ANTISERUM; ANTIVIRUS AGENT; BAVITUXIMAB; BRASSINOSTEROID; CHLOROPHYLLIDE; CONSENSUS INTERFERON; DEF 201; E 567; F 100G 5; FAVIPIRAVIR; FLUOROURACIL; GENISTEIN; LJ 001; MY 24; NSC 14560; NSC 20625; PF 429242; RIBAVIRIN; ST 193; ST 294; STAMPIDINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARENAVIRUS; ARENAVIRUS INFECTION; ARGENTINE HEMORRHAGIC FEVER; CALLITRICHINAE; CHLOROCEBUS; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; EXPERIMENTAL GUINEA PIG; EXPERIMENTAL MOUSE; FATALITY; FEVER; GENE REPLICATION; GUANARITO VIRUS; HAMSTER; HEADACHE; HEMORRHAGIC FEVER; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INFECTION CONTROL; JUNIN VIRUS; LASSA FEVER; LASSA VIRUS; LUJO VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MACHUPO ARENAVIRUS; MUTATION RATE; MYALGIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; SABIA VIRUS; SORE THROAT; VENEZUELAN HEMORRHAGIC FEVER; VIRUS ENTRY; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; ARENAVIRIDAE INFECTIONS; CONTROLLED CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; RIBAVIRIN; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 82455219052     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.132     Document Type: Review

References (127)

1. Bray M. Pathogenesis of viral hemorrhagic fever. Curr. Opin. Immunol. 17(4), 399-403 (2005).
2. Moraz ML, Kunz S. Pathogenesis of arenavirus hemorrhagic fevers. Expert Rev. Anti Infect. Ther. 9(1), 49-59 (2011).
3. Enria DA, Briggiler AM, Sanchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 78(1), 132-139 (2008).
4. Borio L, Inglesby T, Peters CJ et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287(18), 2391-2405 (2002).
5. Fisher-Hoch SP, Tomori O, Nasidi A et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 311(7009), 857-859 (1995).
6. Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin. Infect. Dis. 51(12), 1435-1441 (2010).
7. Khan SH, Goba A, Chu M et al. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res. 78(1), 103-115 (2008).
8. Mccormick JB, King IJ, Webb PA et al. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314(1), 20-26 (1986).
9. Jahrling PB, Peters CJ. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect. Immun. 44(2), 528-533 (1984).
10. Jahrling PB, Frame JD, Rhoderick JB, Monson MH. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans. R. Soc. Trop. Med. Hyg. 79(3), 380-384 (1985).
11. Zapata JC, Pauza CD, Djavani MM et al. Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever. Antiviral Res. 92(2), 125-138 (2011).
12. Paweska JT, Sewlall NH, Ksiazek TG et al. Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg. Infect. Dis. 15(10), 1598-1602 (2009).
13. Enria DA, Ambrosio AM, Briggiler AM, Feuillade MR, Crivelli E. [Candid#1 vaccine against Argentine hemorrhagic fever produced in Argentina. Immunogenicity and safety]. Medicina (Mex.) 70(3), 215-222 (2010).
14. Maiztegui JI, Fernandez NJ, De Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2(8154), 1216-1217 (1979).
15. Enria DA, Briggiler AM, Levis S, Vallejos D, Maiztegui JI, Canonico PG. Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever. Antiviral Res. 7(6), 353-359 (1987).
16. Stephen EL, Jones DE, Peters CJ, Eddy GA, Loizeaux PS, Jahrling PB. Ribavirin treatment of toga-, arena-and bunyavirus infections in subhuman primates and other laboratory animal species. In: Ribavirin: a broad spectrum antiviral agent. Smith RA, Kirkpatrick W (Eds). Academic Press Inc. NY, USA, 168-183 (1980).
17. Kilgore PE, Ksiazek TG, Rollin PE et al. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin. Infect. Dis. 24(4), 718-722 (1997).
18. Delgado S, Erickson BR, Agudo R et al. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog. 4(4), e1000047 (2008).
19. Lisieux T, Coimbra M, Nassar ES et al. New arenavirus isolated in Brazil. Lancet 343(8894), 391-392 (1994).
20. Barry M, Russi M, Armstrong L et al. Brief report: treatment of a laboratory-acquired Sabia virus infection. N. Engl. J. Med. 333(5), 294-296 (1995).
21. Salas R, De Manzione N, Tesh RB et al. Venezuelan haemorrhagic fever. Lancet 338(8774), 1033-1036 (1991).
22. Kolokoltsova OA, Yun NE, Poussard AL et al. Mice lacking interferon {alpha}/{beta} and {gamma} receptors are susceptible to Junin virus infection. J. Virol. 84(24), 13063-13067 (2010).
23. Bradfute SB, Stuthman KS, Shurtleff AC, Bavari S. A STAT-1 knockout mouse model for Machupo virus pathogenesis. Virology J. 8(1), 300 (2011).
24. Flatz L, Rieger T, Merkler D et al. T cell-dependence of Lassa fever pathogenesis. PLoS Pathog. 6(3), e1000836 (2010).
25. Gowen BB, Wong MH, Larson D et al. Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog. PLoS ONE 5(9), e12760 (2010).
26. Gowen BB, Holbrook MR. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res. 78(1), 79-90 (2008).
27. York J, Dai D, Amberg SM, Nunberg JH. pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J. Virol. 82(21), 10932-10939 (2008).
28. Bolken TC, Laquerre S, Zhang Y et al. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. 69(2), 86-97 (2006).
29. Larson RA, Dai D, Hosack VT et al. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 82(21), 10768-10775 (2008).
30. Thomas CJ, Casquilho-Gray HE, York J et al. A specific interaction of small molecule entry inhibitors with the envelope glycoprotein complex of the Junin hemorrhagic fever arenavirus. J. Biol. Chem. 286(8), 6192-6200 (2011).
31. Cashman KA, Smith MA, Twenhafel NA et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res. 90(1), 70-79 (2011).
32. Sidwell RW, Barnard DL, Day CW et al. Efficacy of orally administered T-705 on lethal avian Influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 51(3), 845-851 (2007).
33. Kiso M, Takahashi K, Sakai-Tagawa Y et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl. Acad. Sci. USA 107(2), 882-887 (2010).
34. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob. Agents Chemother. 54(6), 2517-2524 (2010).
35. Furuta Y, Takahashi K, Fukuda Y et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46(4), 977-981 (2002).
36. Furuta Y, Takahashi K, Kuno-Maekawa M et al. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49(3), 981-986 (2005).
37. Furuta Y, Takahashi K, Shiraki K et al. T-705 (favipiravir) and related compounds. Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 82(3), 95-102 (2009).
38. Gowen BB, Wong MH, Jung KH et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51(9), 3168-3176 (2007).
39. Gowen BB, Smee DF, Wong MH et al. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS ONE 3(11), e3725 (2008).
40. Mendenhall M, Russell A, Smee DF et al. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLoS Negl. Trop. Dis. 5(10), e1342 (2011).
41. Mendenhall M, Russell A, Juelich T et al. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob. Agents Chemother. 55(2), 782-787 (2011).
42. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3(5), 330-338 (2003).
43. Ruiz-Jarabo CM, Ly C, Domingo E, De La Torre JC. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308(1), 37-47 (2003).
44. Grande-Perez A, Lazaro E, Lowenstein P, Domingo E, Manrubia SC. Suppression of viral infectivity through lethal defection. Proc. Natl Acad. Sci. USA 102(12), 4448-4452 (2005).
45. Grande-Perez A, Sierra S, Castro MG, Domingo E, Lowenstein PR. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc. Natl Acad. Sci. USA 99(20), 12938-12943 (2002).
46. Uckun FM, Petkevich AS, Vassilev AO, Tibbles HE, Titov L. Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect. Dis. 4, 14 (2004).
47. Cummins D, Bennett D, Fisher-Hoch SP, Farrar B, Machin SJ, Mccormick JB. Lassa fever encephalopathy: clinical and laboratory findings. J. Trop. Med. Hyg. 95(3), 197-201 (1992).
48. Solbrig MV, Mccormick JB. Lassa fever: central nervous system manifestations. J. Trop. Geogr. Neurol. 1, 23-30 (1991).
49. Akiyama T, Ishida J, Nakagawa S et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. TJ. Trop. Med. Chem. 262(12), 5592-5595 (1987).
50. Vela EM, Bowick GC, Herzog NK, Aronson JF. Genistein treatment of cells inhibits arenavirus infection. Antiviral Res. 77(2), 153-156 (2008).
51. Vela EM, Knostman KA, Mott JM et al. Genistein, a general kinase inhibitor, as a potential antiviral for arenaviral hemorrhagic fever as described in the Pirital virus-Syrian golden hamster model. Antiviral Res. 87(3), 318-328 (2010).
52. Vela EM, Bowick GC, Herzog NK, Aronson JF. Exploring kinase inhibitors as therapies for human arenavirus infections. Future Virol. 3(3), 243-251 (2008).
53. Damm EM, Pelkmans L, Kartenbeck J, Mezzacasa A, Kurzchalia T, Helenius A. Clathrin-and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae. J. Cell Biol. 168(3), 477-488 (2005).
54. Pannetier D, Faure C, Georges-Courbot MC, Deubel V, Baize S. Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection. J. Virol. 78(19), 10516-10524 (2004).
55. Martinez-Sobrido L, Giannakas P, Cubitt B, Garcia-Sastre A, De La Torre JC. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J. Virol. 81(22), 12696-12703 (2007).
56. Marq JB, Hausmann S, Veillard N, Kolakofsky D, Garcin D. Short double-stranded RNAs with an overhanging 5' ppp-nucleotide, as found in arenavirus genomes, act as RIG-I decoys. J. Biol. Chem. 286(8), 6108-6116 (2011).
57. Fan L, Briese T, Lipkin WI. Z proteins of New World arenaviruses bind RIG-I and interfere with type I interferon induction. J. Virol. 84(4), 1785-1791 (2010).
58. Baize S, Marianneau P, Loth P et al. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J. Virol. 83(11), 5890-5903 (2009).
59. Gowen BB, Barnard DL, Smee DF et al. Interferon alfacon-1 protects hamsters from lethal pichinde virus infection. Antimicrob. Agents Chemother. 49(6), 2378-2386 (2005).
60. Gowen BB, Smee DF, Wong MH et al. Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters. Antivir. Chem. Chemother. 17(4), 175-183 (2006).
61. Gowen BB, Ennis J, Russell A, Sefing EJ, Wong MH, Turner J. Use of recombinant adenovirus vectored consensus IFN-a to avert severe arenavirus infection. PLoS ONE 6(10), e26072 (2011).
62. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89(4), 1121-1132 (1997).
63. Soares MM, King SW, Thorpe PE. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat. Med. 14(12), 1357-1362 (2008).
64. Hoffmann PR, Kench JA, Vondracek A et al. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J. Immunol. 174(3), 1393-1404 (2005).
65. Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat. Med. 10(Suppl. 12), S110-S121 (2004).
66. Zhou S, Cerny AM, Bowen G et al. Discovery of a novel TLR2 signaling inhibitor with anti-viral activity. Antiviral Res. 87(3), 295-306 (2010).
67. Lee AY, Vlasuk GP. Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J. Intern. Med. 254(4), 313-321 (2003).
68. Bergum PW, Cruikshank A, Maki SL, Kelly CR, Ruf W, Vlasuk GP. Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2. J. Biol. Chem. 276(13), 10063-10071 (2001).
69. Geisbert TW, Hensley LE, Jahrling PB et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362(9400), 1953-1958 (2003).
70. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB et al. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J. Infect. Dis. 196(Suppl. 2), S372-S381 (2007).
71. Jones CA, London NR, Chen H et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat. Med. 14(4), 448-453 (2008).
72. London NR, Zhu W, Bozza FA et al. Targeting Robo4-dependent slit signaling to survive the cytokine storm in sepsis and influenza. Sci. Transl. Med. 2(23), 23ra19 (2010).
73. Gowen BB, Julander JG, London NR et al. Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virol J. 7, 240 (2010).
74. Stephen EL, Jahrling PB. Experimental Lassa fever virus infection successfully treated with ribavirin. Lancet 1(8110), 268-269 (1979).
75. Kiley MP, Lange JV, Johnson KM. Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet 2(8145), 738 (1979).
76. Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT, Stephen EL. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 141(5), 580-589 (1980).
77. Stephenson EH, Larson EW, Dominik JW. Effect of environmental factors on aerosol-induced Lassa virus infection. J. Med. Virol. 14(4), 295-303 (1984).
78. Jahrling PB, Peters CJ, Stephen EL. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J. Infectious Dis. 149(3), 420-427 (1984).
79. Hensley LE, Smith MA, Geisbert JB et al. Pathogenesis of lassa fever in cynomolgus macaques. Virology J. 8, 205 (2011).
80. Carrion R Jr, Brasky K, Mansfield K et al. Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J. Virol. 81(12), 6482-6490 (2007).
81. Walker DH, Wulff H, Lange JV, Murphy FA. Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull. World Health Organ. 52(4-6), 523-534 (1975).
82. Jahrling PB, Smith S, Hesse RA, Rhoderick JB. Pathogenesis of Lassa virus infection in guinea pigs. Infect. Immun. 37(2), 771-778 (1982).
83. Lukashevich IS, Djavani M, Rodas JD et al. Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus. J. Med. Virol. 67(2), 171-186 (2002).
84. Jahrling PB, Hesse RA, Rhoderick JB, Elwell MA, Moe JB. Pathogenesis of a pichinde virus strain adapted to produce lethal infections in guinea pigs. Infect. Immun. 32(2), 872-880 (1981).
85. Connolly BM, Jenson AB, Peters CJ, Geyer SJ, Barth JF, Mcpherson RA. Pathogenesis of Pichinde virus infection in strain 13 guinea pigs: an immunocytochemical, virologic, and clinical chemistry study. Am. J. Trop. Med. Hyg. 49(1), 10-24 (1993).
86. Aronson JF, Herzog NK, Jerrells TR. Pathological and virological features of arenavirus disease in guinea pigs. Comparison of two Pichinde virus strains. Am. J. Pathol. 145(1), 228-235 (1994).
87. Buchmeier MJ, Rawls WE. Variation between strains of hamsters in the lethality of Pichinde virus infections. Infect. Immun. 16(2), 413-421 (1977).
88. Murphy FA, Buchmeier MJ, Rawls WE. The reticuloendothelium as the target in a virus infection. Pichinde virus pathogenesis in two strains of hamsters. Lab. Invest. 37(5), 502-515 (1977).
89. Xiao SY, Zhang H, Yang Y, Tesh RB. Pirital virus (Arenaviridae) infection in the syrian golden hamster, Mesocricetus auratus: a new animal model for arenaviral hemorrhagic fever. Am. J. Trop. Med. Hyg. 64(3-4), 111-118 (2001).
90. Sbrana E, Mateo RI, Xiao SY, Popov VL, Newman PC, Tesh RB. Clinical laboratory, virologic, and pathologic changes in hamsters experimentally infected with Pirital virus (Arenaviridae): a rodent model of Lassa fever. Am. J. Trop. Med. Hyg. 74(6), 1096-1102 (2006).
91. Mckee KT Jr, Mahlandt BG, Maiztegui JI, Eddy GA, Peters CJ. Experimental Argentine hemorrhagic fever in rhesus macaques: viral strain-dependent clinical response. J. Infectious Dis. 152(1), 218-221 (1985).
92. Green DE, Mahlandt BG, Mckee KT Jr. Experimental Argentine hemorrhagic fever in rhesus macaques: virus-specific variations in pathology. J. Med. Virol. 22(2), 113-133 (1987).
93. Weissenbacher MC, Calello MA, Colillas OJ, Rondinone SN, Frigerio MJ. Argentine hemorrhagic fever: a primate model. Intervirology 11(6), 363-365 (1979).
94. Gonzalez PH, Laguens RP, Frigerio MJ, Calello MA, Weissenbacher MC. Junin virus infection of Callithrix jacchus: pathologic features. Am. J. Trop. Med. Hyg. 32(2), 417-423 (1983).
95. Molinas FC, Paz RA, Rimoldi MT, De Bracco MM. Studies of blood coagulation and pathology in experimental infection of guinea pigs with Junin virus. J. Infect. Dis. 137(6), 740-746 (1978).
96. Oubina JR, Carballal G, Videla CM, Cossio PM. The guinea pig model for Argentine hemorrhagic fever. Am. J. Trop. Med. Hyg. 33(6), 1251-1257 (1984).
97. Yun NE, Linde NS, Dziuba N et al. Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs. Am. J. Trop. Med. Hyg. 79(2), 275-282 (2008).
98. Terrell TG, Stookey JL, Eddy GA, Kastello MD. Pathology of Bolivian hemorrhagic fever in the rhesus monkey. Am. J. Pathol. 73(2), 477-494 (1973).
99. Eddy GA, Scott SK, Wagner FS, Brand OM. Pathogenesis of Machupo virus infection in primates. Bull. World Health Organ. 52(4-6), 517-521 (1975).
100. Kastello MD, Eddy GA, Kuehne RW. A rhesus monkey model for the study of Bolivian hemorrhagic fever. J. Infect. Dis. 133(1), 57-62 (1976).
101. Wagner FS, Eddy GA, Brand OM. The African green monkey as an alternate primate host for studying Machupo virus infection. Am. J. Trop. Med. Hyg. 26(1), 159-162 (1977).
102. Mcleod CG Jr, Stookey JL, White JD, Eddy GA, Fry GA. Pathology of Bolivian hemorrhagic fever in the African green monkey. Am. J. Trop. Med. Hyg. 27(4), 822-826 (1978).
103. Webb PA, Justines G, Johnson KM. Infection of wild and laboratory animals with Machupo and Latino viruses. Bull. World Health Organ. 52(4-6), 493-499 (1975).
104. Hall WC, Geisbert TW, Huggins JW, Jahrling PB. Experimental infection of guinea pigs with Venezuelan hemorrhagic fever virus (Guanarito): a model of human disease. Am. J. Trop. Med. Hyg. 55(1), 81-88 (1996).
105. Lee AM, Rojek JM, Gundersen A et al. Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. Virology 372(1), 107-117 (2008).
106. Lee AM, Rojek JM, Spiropoulou CF et al. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J. Biol. Chem. 283(27), 18734-18742 (2008).
107. York J, Berry JD, Stroher U et al. An antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion. J. Virol. 84(12), 6119-6129 (2010).
108. Guo H, Pan X, Mao R et al. Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses. Antimicrob. Agents Chemother. 55(2), 478-486 (2011).
109. Wolf MC, Freiberg AN, Zhang T et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl Acad. Sci. USA 107(7), 3157-3162 (2010).
110. Muller S, Gunther S. Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus. Antimicrob. Agents Chemother. 51(6), 2215-2218 (2007).
111. Sepulveda CS, Garcia CC, Damonte EB. Inhibition of arenavirus infection by thiuram and aromatic disulfides. Antiviral Res. 87(3), 329-337 (2010).
112. Garcia CC, Candurra NA, Damonte EB. Antiviral and virucidal activities against arenaviruses of zinc-finger active compounds. Antivir. Chem. Chemother. 11(3), 231-237 (2000).
113. Garcia CC, Djavani M, Topisirovic I, Borden KL, Salvato MS, Damonte EB. Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds. J. Gen. Virol. 87(Pt 5), 1217-1228 (2006).
114. Garcia CC, Ellenberg PC, Artuso MC, Scolaro LA, Damonte EB. Characterization of Junin virus particles inactivated by a zinc finger-reactive compound. Virus Res. 143(1), 106-113 (2009).
115. Artuso MC, Ellenberg PC, Scolaro LA, Damonte EB, Garcia CC. Inhibition of Junin virus replication by small interfering RNAs. Antiviral Res. 84(1), 31-37 (2009).
116. Rojek JM, Pasqual G, Sanchez AB, Nguyen NT, De La Torre JC, Kunz S. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J. Virol. 84(1), 573-584 (2010).
117. Maisa A, Stroher U, Klenk HD, Garten W, Strecker T. Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants. PLoS Negl. Trop. Dis. 3(6), e446 (2009).
118. Urata S, Yun N, Pasquato A, Paessler S, Kunz S, De La Torre JC. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J. Virol. 85(2), 795-803 (2011).
119. Cordo SM, Candurra NA, Damonte EB. Myristic acid analogs are inhibitors of Junin virus replication. Microbes Infect. 1(8), 609-614 (1999).
120. Asper M, Sternsdorf T, Hass M et al. Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J. Virol. 78(6), 3162-3169 (2004).
121. Barradas JS, Errea MI, D'accorso NB, Sepulveda CS, Damonte EB. Imidazo[2,1-b] thiazole carbohydrate derivatives: Synthesis and antiviral activity against Junin virus, agent of Argentine hemorrhagic fever. Eur. J. Med. Chem. 46(1), 259-264 (2011).
122. Barradas JS, Errea MI, D'accorso NB, Sepulveda CS, Talarico LB, Damonte EB. Synthesis and antiviral activity of azoles obtained from carbohydrates. Carbohydr. Res. 343(14), 2468-2474 (2008).
123. Garcia CC, Candurra NA, Damonte EB. Differential inhibitory action of two azoic compounds against arenaviruses. Int. J. Antimicrob. Agents 21(4), 319-324 (2003).
124. Wachsman MB, Lopez EM, Ramirez JA, Galagovsky LR, Coto CE. Antiviral effect of brassinosteroids against herpes virus and arenaviruses. Antivir. Chem. Chemother. 11(1), 71-77 (2000).
125. Acosta EG, Bruttomesso AC, Bisceglia JA, Wachsman MB, Galagovsky LR, Castilla V. Dehydroepiandrosterone, epiandrosterone and synthetic derivatives inhibit Junin virus replication in vitro. Virus Res. 135(2), 203-212 (2008).
126. Sepulveda CS, Fascio ML, Mazzucco MB et al. Synthesis and evaluation of N-substituted acridones as antiviral agents against haemorrhagic fever viruses. Antivir. Chem. Chemother. 19(1), 41-47 (2008).
127. Garcia CC, Brousse BN, Carlucci MJ et al. Inhibitory effect of thiosemicarbazone derivatives on Junin virus replication in vitro. Antivir. Chem. Chemother. 14(2), 99-105 (2003).